- Home
- HFRO vs GHRS Comparison
HFRO vs GHRS Comparison
Compare HFRO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- GHRS
- Stock Information
- Founded
- HFRO 2000
- GHRS 2018
- Country
- HFRO United States
- GHRS Ireland
- Employees
- HFRO N/A
- GHRS N/A
- Industry
- HFRO Finance/Investors Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- HFRO Finance
- GHRS Health Care
- Exchange
- HFRO Nasdaq
- GHRS Nasdaq
- Market Cap
- HFRO 388.8M
- GHRS 402.7M
- IPO Year
- HFRO N/A
- GHRS 2021
- Fundamental
- Price
- HFRO $5.52
- GHRS $7.97
- Analyst Decision
- HFRO
- GHRS Strong Buy
- Analyst Count
- HFRO 0
- GHRS 3
- Target Price
- HFRO N/A
- GHRS $35.67
- AVG Volume (30 Days)
- HFRO 421.7K
- GHRS 55.0K
- Earning Date
- HFRO 01-01-0001
- GHRS 11-14-2024
- Dividend Yield
- HFRO 12.00%
- GHRS N/A
- EPS Growth
- HFRO N/A
- GHRS N/A
- EPS
- HFRO 1.23
- GHRS N/A
- Revenue
- HFRO $44,535,929.00
- GHRS N/A
- Revenue This Year
- HFRO N/A
- GHRS N/A
- Revenue Next Year
- HFRO N/A
- GHRS N/A
- P/E Ratio
- HFRO $5.50
- GHRS N/A
- Revenue Growth
- HFRO N/A
- GHRS N/A
- 52 Week Low
- HFRO $5.92
- GHRS $5.08
- 52 Week High
- HFRO $9.38
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- HFRO 38.63
- GHRS 45.97
- Support Level
- HFRO $5.73
- GHRS $7.29
- Resistance Level
- HFRO $5.82
- GHRS $8.91
- Average True Range (ATR)
- HFRO 0.09
- GHRS 0.79
- MACD
- HFRO -0.02
- GHRS -0.08
- Stochastic Oscillator
- HFRO 0.00
- GHRS 31.55
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. The company's portfolio of investments includes different industry investments such as Financial, Communication Services, Energy, Healthcare, Materials, and others.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.